Medical Device Network

French Government offer reimbursement for Dexcom’s ONE CGM

The reimbursement guidance offers 100,000 T2D patients who are already on basal insulin injections access to Dexcom’s ONE CGM.

The French Government are to offer national reimbursement for DexCom’s ONE continuous glucose monitor (CGM) to patients treating their type 2 diabetes (T2D) with basal insulin injections.

The reimbursement guidance applies to 100,000 people aged over two years old on non-intensified insulin therapy (fewer than three injections daily) with insufficient glycaemic control.

The Dexcom ONE system allows for real-time monitoring of blood glucose by both the user and up to ten additional people to allow for shared monitoring. The technology can be worn on the abdomen, back of upper arms, or upper buttocks in children aged 2-17 years. It consists of a waterproof sensor that measures blood glucose, a transmitter that sends CGM readings and a Dexcom One smartphone-compatible app.

The French Government is the first country in Europe to offer full national reimbursement for Dexcom CGM technology to those treating T2D with basal injections, following other countries around the world such as the US and New Zealand.

The most covered and reimbursed CGM manufacturer in the US, Dexcom recently launched its updated ONE device, ONE+, in the UK. The Dexcom ONE+ system features a one-touch sensor applicator, differing from Dexcom ONE which has a separate transmitter. It is 60% smaller than the ONE device. Dexcom inked a deal with the National Health Service (NHS) in 2022 for CGM devices, which increased the Dexcom user base from 270,000 users at the end of 2017 to 1.7 million users globally at the end of 2022.

Dexcom also released its State of Type 2 report last month, indicating that CGM usage amongst people with T2D can lead to greater user motivation and improved diabetes management. Out of the diabetes patients who suffer from negative mental health, 48% said being able to monitor their glucose levels would help them better manage the condition.

As diabetes prevalence increases globally, the market for CGM is also growing. The wearable device sector has seen technological advancements over the past few years, with some devices even being set up with an insulin pump to automatically adjust blood glucose levels. According to a GlobalData market model, the insulin pumps and CGM market in France will be worth $459.1m in 2033, increasing from $230.1m in 2023.

Dexcom’s EMEA and LATAM general manager Alex Moussa said: “The decision by the French government to offer national reimbursement for Dexcom CGM to those treating their type 2 diabetes with basal insulin injections is a significant step forward in both the treatment and understanding of type 2 diabetes on both an individual and societal level.”